I have a fasta file with gene sequences - are there existing tools / pipelines that calculate & quantify the variable and conserved regions? Assuming that there has to be an accepted protocol / method for this but haven't found anything...
-
-
Are the sequences from one gene (or multiple genes)? Generally a multiple sequence alignment (MSA) will give you this information. -
the sequences are all from one gene...Comment
-
Look into clustalW (or clustal omega if these are protein sequences). T-coffee/MUSCLE/MAFFT are all programs that can be used (http://www.ebi.ac.uk/Tools/msa/) for alignments as well. You may need to download and run the programs locally if you have a large number of sequences.
What exactly are you looking for in terms of "calculate and quantify"?Comment
-
what I'm looking to do is take the reads from a sequencing run and 'ensure' (as best I can) that the correct target section was in fact amplified... I have run the reads through usearch against a database of target gene sequences - but I am trying to see what kind of variability may be expected by calculating the existing variability in the known / published gene sequences...Comment
-
If your data is still in the form of individual reads then you may want to use an NGS aligner (BBMap, bowtie2, BWA) to align them the gene (or genes?) region and create a BAM. Then you can use samtools/bcftools to call SNP's/get a consensus sequence for the gene(s).Comment
-
yeah, I aligned them w/ bwa, created a bam file and then viewed them in igv and the reads - or 54% of them - are aligning along the bacterial genome where the gene is located...
but since it is coming from a clinical sample I am trying to see what the variability is along the existing db of sequenced genes to have something to help put the alignment score into perspective... I think I'll just write a simple script to calculate the base abundance once muscle finishes aligning the existing sequences...Comment
-
Researchers using sequencing and genomics tools often have to make trade-offs. They can choose between speed or scale, short reads or long-range information, or targeted panels or a view of the whole transcriptome. New technologies that have been released this year are built to address those tough choices.
We asked six companies the same four questions to learn about their latest products. The new technologies bring a lot to the table, including rethinking sequencing...
Comment